rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IRD
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Opus Genetics misses Q3 estimates on revenue and earnings
      Nov 10Investing.comIRD
      Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update

      OPGx-BEST1 Cohort 2 Dosing Complete and Data Expected in Q1 2027 OPGx-LCA5 Registrational Phase 3 Trial Fully Enrolled with Initiation of Dosing Expected in Q4 2026 FDA Clearance of IND for OPGx-RDH12, with Phase 1/2 Trial Dosing Planned for Q4 2026 FDA Approval of Phentolamine Ophthalmic Solution 0.75% for Presbyopia Triggers Milestone Payment Cash Runway into 2029 Expected to Support Multiple Clinical Inflection Points and Opportunities for Priority Review Vouchers RESEARCH TRIANGLE PARK, N.C.

      Nov 10Yahoo FinanceIRD
      Opus Genetics completes dosing in gene therapy trial cohort
      Nov 5Investing.comIRD
      Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference
      Nov 3Yahoo FinanceIRD
      Opus Genetics appoints chief scientific officer, operations head
      Oct 29Investing.comIRD
      Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations
      Oct 29Yahoo FinanceIRD
      Opus Genetics president Yerxa sells $117,364 in IRD stock
      Oct 28Investing.comIRD
      Opus Genetics COO Schachle reports $16,994 stock sale for taxes
      Oct 27Investing.comIRD
      Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval
      Oct 25Yahoo FinanceIRD
      Opus Genetics receives FDA clearance for RDH12-LCA gene therapy
      Oct 21Investing.comIRD
      Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness
      Oct 21Yahoo FinanceIRD
      Opus Genetics at Chardan’s 10th annual healthcare conference: pipeline gains
      Oct 20Investing.comIRD
      Opus Genetics stock rating maintained at outperform by Citizens
      Oct 19Investing.comIRD
      Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment
      Oct 16Yahoo FinanceIRD
      Opus Genetics Says FDA Approves Supplemental Application for Presbyopia Treatment
      Oct 16Yahoo FinanceIRD
      Viatris, Opus win FDA label expansion for Ryzumvi (VTRS:NASDAQ)

      Viatris (VTRS) and Opus Genetics (IRD) win FDA label expansion for the Ryzumvi eye care solution as a treatment for presbyopia. Read more here.

      Oct 16Seeking AlphaIRDVTRS
      FDA approves Opus Genetics’ eye drops for presbyopia treatment
      Oct 16Investing.comIRD
      Citizens reiterates Opus Genetics stock rating on cohort progress
      Oct 16Investing.comIRD
      Opus Genetics reports early trial results for gene therapies
      Oct 15Investing.comIRD
      Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
      Oct 15Yahoo FinanceIRD
      Opus Genetics to Present at the Chardan Annual Healthcare Conference
      Oct 13Yahoo FinanceIRD
      Could an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff?
      Oct 8Yahoo FinanceIRDVTRS
      Analysts Are Bullish on Top Healthcare Stocks: McKesson (MCK), Opus Genetics (IRD)

      Detailed price information for Mckesson Corp (MCK-N) from The Globe and Mail including charting and trades.

      Oct 6The Globe and MailIRD
      Opus Genetics, Inc. (IRD) Presents at Euretina 2026 - Slideshow (NASDAQ:IRD) 2026-10-04

      2026-10-04. The following slide deck was published by Opus Genetics, Inc.

      Oct 5Seeking AlphaIRD
      Foundation fighting blindness fund sells $2.75m in Opus Genetics stock
      Oct 3Investing.comIRD
      Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified?

      Opus Genetics, Inc. (NASDAQ:IRD) reported on September 9 that all five low-dose BIRD-1 participants showed clinically meaningful improvement on at least one visual-function measure after treatment with investigational gene therapy OPGx-BEST1. The open-label Phase 1/2 cohort included three participants with Best vitelliform macular dystrophy followed for three months and two with autosomal recessive bestrophinopathy followed […]

      Sep 16Yahoo FinanceIRD
      NEWSLETTER: Experimental eye drops ease night vision problems for drivers
      Sep 11ReutersIRD
      Opus Genetics: A Resounding Study Success Merits A Higher Valuation (NASDAQ:IRD)
      Sep 10Seeking AlphaIRD
      Correction: Chardan Raises Price Target on Opus Genetics to $16 From $13, Keeps Buy Rating

      (Corrects ticker to IRD.) Opus Genetics (IRD) has an average rating of buy and mean price target

      Sep 10Yahoo FinanceIRD
      Chardan Raises Price Target on Opus Genetics to $16 From $13, Keeps Buy Rating

      Opus Genetics (IRD) has an average rating of buy and mean price target of $13, according to analysts

      Sep 10Yahoo FinanceIRD
      Wedbush Raises Price Target on Opus Genetics to $13 From $10, Keeps Outperform Rating

      Opus Genetics (IRD) has an average rating of buy and mean price target of $13, according to analysts

      Sep 10Yahoo FinanceIRD
      Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial - Slideshow
      Sep 9Seeking AlphaIRD
      IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial

      Researchers observed structural improvements in the retina in four of five patients being evaluated in a Phase 1/2 study

      Sep 9Yahoo FinanceIRD
      12 Health Care Stocks Moving In Wednesday's Intraday Session
      Sep 9BenzingaIRD
      Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says
      Sep 9BenzingaIRD
      Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data, Targets Potential Phase 3 Dosing in 2027

      Opus Genetics (NASDAQ:IRD) reported positive low-dose Cohort 1 data from its Phase 1/2 BIRD-1 trial of OPGx-BEST1, alongside FDA alignment on potential pivotal endpoints and a development path that could lead to Phase 3 participant dosing in 2027. Key Investor TakeawaysAll five low-dose participants showed clinically meaningful improvement in at least one measure of visual function, while four of five showed structural retinal improvements.

      Sep 9Yahoo FinanceIRD
      Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving High
      Sep 9BenzingaIRDCALFTK
      Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
      Sep 9Yahoo FinanceIRD
      Wedbush Raises Opus Genetics Price Target to $13 From $10, Maintains Outperform Rating

      Opus Genetics (IRD) has an average rating of buy and mean price target of $10.71, according to analy

      Sep 9Yahoo FinanceIRD
      Wedbush raises Opus Genetics stock price target on FDA alignment
      Sep 9Investing.comIRD
      Opus Genetics stock rating reaffirmed at Buy by H.C. Wainwright
      Sep 8Investing.comIRD
      Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences

      Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ET Full clinical dataset and additional analyses evaluating key measures of visual function to be presented at upcoming medical meetings RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (“Opus” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and

      Sep 2Yahoo FinanceIRD
      Opus Genetics shares rise 5.9% ahead of OPGx-BEST1 trial data

      Opus Genetics Inc (NASDAQ:IRD) shares rose 5. 9% in pre-market trading ahead of the scheduled release of three-month topline data from Cohort 1 of its OPGx-BEST1 Phase 1/2 clinical trial.

      Sep 1Yahoo FinanceIRD
      Why is Opus Genetics stock rallying today?
      Sep 1Investing.comIRD
      Citizens reiterates Opus Genetics stock rating on Viatris partnership potential
      Aug 28Investing.comIRDVTRS

      This is the newest page. Registered accounts read further back.